Abstract
Some RCT have shown lower clinical deterioration rate in COVID-19 patients randomized to colchicine (GRECCO-19) and also have shown a better survival rate. A more recent study (COLCORONA) has shown no difference in the primary endpoint of the study that was a composite of death or hospitalization by Day 30. We conduct an observational proof of concept study to evaluate the efficacy and safety of low dose colchicine as a prophylactic agent to prevent severe SARS-CoV-2 infection in end stage kidney disease (ESKD) patients on maintenance hemodialysis (HD).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
